Redeye maintains Medicover's valuation at SEK 152 per share after today's strong report. Medicover has delivered a solid performance and is emerging stronger from the crisis: recovery of the fee-for-service business, growing membership base, solid covid-19 related revenues have resulted in an impressive bottom line, given the circumstances. We expect this solid performance to continue.